<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prior studies indicate that alpha-alpha diaspirin crosslinked <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (DCLHb) decreases <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>One mechanism whereby DCLHb may ameliorate <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> is by binding nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO), which has been implicated as neurotoxic </plain></SENT>
<SENT sid="2" pm="."><plain>We assessed the effect of L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (NO synthase inhibitor) and <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> (NO substrate) on ischemic brain injury after DCLHb infusion </plain></SENT>
<SENT sid="3" pm="."><plain>Rats were randomized to one of the following groups: Control-no hematocrit manipulation; DCLHb-hematocrit decreased to 16% with 10% DCLHb; DCLHb/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>-hematocrit decreased to 16% with DCLHb, and L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> given; DCLHb/L-arg-hematocrit decreased to 16% with DCLHb, and <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> given </plain></SENT>
<SENT sid="4" pm="."><plain>After 90-min of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and 4-hr of reperfusion, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was determined with TTC stain </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume (mm3, mean +/- SD) was greater in the Control group (142 +/- 16) than the DCLHb (43 +/- 12), DCLHb/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (45 +/- 14), and DCLHb/L-arg (71 +/- 18) groups (p &lt; 0.05); was greater in the DCLHb/L-arg group than the DCLHb and DCLHb/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> groups (p &lt; 0.05); but was not different between the DCLHb and DCLHb/L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> groups </plain></SENT>
<SENT sid="6" pm="."><plain>These data indicate that DCLHb decreases ischemic brain injury, and that binding NO may be one mechanism by which DCLHb decreases ischemic brain injury </plain></SENT>
</text></document>